Loading…
← CockpitCompetitor Analysis › 2595.HK Genfleet Therapeutics (Shanghai), Inc. Class HOpen in the cockpit ↗

Genfleet Therapeutics (Shanghai), Inc. Class H2595.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.

≈ A Chinese Mirati Therapeutics-style KRAS/oncology biotechMomentum laggard 12
Mkt cap
$912M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$9.80M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · HKDHK$19.72
1D+1.2%
1W-16.7%
1M-33.6%
3M-33.8%
6M-42.4%
YTD-17.1%
1Y-32.6%
ATR %11.4%
52w lowhigh62.7% off high

What Genfleet Therapeutics (Shanghai) does

Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.

In one line: A Chinese Mirati Therapeutics-style KRAS/oncology biotech.

Products and services

  • KRAS-pathway inhibitor pipeline
  • Other oncology small molecules

Customers

  • Licensing/pharma partners
  • Hospitals (post-approval)

Where it sits in the supply chain

  • Biotechnology
  • Small-molecule oncology drugs
  • Clinical-stage pipeline

What could go right

  • Licensing deals with global pharma

What could go wrong

  • Clinical trial failure risk
  • Pre-revenue cash burn

Moat: narrow (IP / patents). Patent-protected small-molecule oncology candidates targeting hard-to-drug pathways.

Headquarters: Shanghai, China · Founded: 2017 · Employees: 102

Named competitors

Genfleet Therapeutics (Shanghai) at a glance

Size Genfleet Therapeutics (Shanghai) (2595.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $912M, the 601st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.72 on 18 Nov 2026.

Performance Over six months the shares fell 42.4%, against -16.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 55.1% over the last twelve months (peer median +6.8%); the operating margin is -456.9% (peer median 8.0%).

Valuation It trades at 55.9× enterprise value to sales against a peer median of 3.2× (most expensive of 19).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 842595.HK 54
Six months, rebased to 100: Genfleet Therapeutics (Shanghai) against the median of its 20 peers (local-currency closes).

Genfleet Therapeutics (Shanghai) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$93.9MHK$141MHK$114MHK$81.5MHK$122M
Revenue growth—+24%+39%-33%—
Gross profitHK$28.7MHK$80.1MHK$76.2MHK$60.8MHK$88.2M
EBITDA-HK$419M-HK$268M-HK$296M-HK$300M-HK$284M
Net income-HK$1.45B-HK$1.95B-HK$735M-HK$562M-HK$320M
Free cash flow-HK$425M-HK$150M-HK$225M-HK$224M-HK$348M
Capital expenditureHK$6.32MHK$121,467HK$290,572HK$656,369HK$13.8M
Total debtn/aHK$113MHK$73.8MHK$34.9MHK$61.2M

Quarterly statements and history in the cockpit →

Genfleet Therapeutics (Shanghai) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%IMTXMLTX6885531795300401039200AKTS6881770005976002526004226035382005SANOFICONRPHARM0061202595.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Genfleet Therapeutics (Shanghai) is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×IMTX6885531795300401039200AKTS6881770005972595.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Genfleet Therapeutics (Shanghai) is the large dot.

Genfleet Therapeutics (Shanghai) competitors and peer comparison

Head to head with its named competitors (2595.HK vs BMY vs 9969.HK vs 6855.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Genfleet Therapeutics (Shanghai) 2595.HK$912M-42%-55%-457%55.9×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
InnoCare Pharma 9969.HK$2.01B-10%+146%35%2.8×-2.0%
Ascentage Pharma Group International 6855.HK$1.18B-34%+70%-220%13.2×n/a

How Genfleet Therapeutics (Shanghai) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Genfleet Therapeutics (Shanghai) against its 20 peers (data as of 18 Nov 2026)
Measure2595.HKPeer medianRank in peer set
1-month return-33.6%-8.3%lowest of 21
6-month return-42.4%-16.9%3rd lowest of 20
Distance from 52-week high-62.7%-44.2%2nd lowest of 21
Revenue growth (TTM)-55.1%+6.8%lowest of 19
Operating margin-456.9%8.0%3rd lowest of 19
EV / Sales55.9×3.2×most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a

Questions

Who are Genfleet Therapeutics (Shanghai)'s main competitors?
Named competitors: Mirati Therapeutics (BMS) (BMY), InnoCare Pharma (9969.HK), Ascentage Pharma (6855.HK). The cockpit's measured peer set (industry) also includes Immatics (IMTX), MoonLake Immunotherapeutics (MLTX), Sichuan Huiyu Pharmaceutical (688553.SS), Lotus Pharmaceutical (1795.TW), Zhejiang Garden Biopharmaceutical (300401.SZ), Oscotec (039200.KS).
Is Genfleet Therapeutics (Shanghai) expensive compared with its peers?
On ev / sales it trades at 55.9× against a peer median of 3.2×, most expensive of 19 in its peer set.
How has Genfleet Therapeutics (Shanghai) stock performed?
Over six months to 18 Nov 2026 the shares returned -42.4% against -16.9% for the median peer; over one year -32.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.